Biologics in Pediatric Rheumatology

Quo Vadis?

Yonit Sterba, Norman Todd Ilowite

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

The past two decades have brought immense satisfaction to pediatric rheumatologists and families of children with rheumatologic diseases. We have been able to better classify, recognize, and diagnose rheumatologic diseases, but most importantly, the discovery of biologic therapies and their efficacy and relative safety in treating multiple rheumatologic conditions, improving quality of life for the patients we care for. We will review the advances of the past two decades and discuss potential areas for new discoveries.

Original languageEnglish (US)
Article number45
JournalCurrent Rheumatology Reports
Volume18
Issue number7
DOIs
StatePublished - Jul 1 2016

Fingerprint

Rheumatology
Biological Products
Pediatrics
Biological Therapy
Patient Care
Quality of Life
Safety
Rheumatologists

Keywords

  • Abatacept
  • IL-1 inhibitors
  • IL-6 inhibitors
  • Juvenile idiopathic arthritis (JIA)
  • Rituximab
  • TNF inhibitors
  • Tofacitinib

ASJC Scopus subject areas

  • Rheumatology

Cite this

Biologics in Pediatric Rheumatology : Quo Vadis? / Sterba, Yonit; Ilowite, Norman Todd.

In: Current Rheumatology Reports, Vol. 18, No. 7, 45, 01.07.2016.

Research output: Contribution to journalReview article

@article{8d267379a6b44d37bb30629a82793294,
title = "Biologics in Pediatric Rheumatology: Quo Vadis?",
abstract = "The past two decades have brought immense satisfaction to pediatric rheumatologists and families of children with rheumatologic diseases. We have been able to better classify, recognize, and diagnose rheumatologic diseases, but most importantly, the discovery of biologic therapies and their efficacy and relative safety in treating multiple rheumatologic conditions, improving quality of life for the patients we care for. We will review the advances of the past two decades and discuss potential areas for new discoveries.",
keywords = "Abatacept, IL-1 inhibitors, IL-6 inhibitors, Juvenile idiopathic arthritis (JIA), Rituximab, TNF inhibitors, Tofacitinib",
author = "Yonit Sterba and Ilowite, {Norman Todd}",
year = "2016",
month = "7",
day = "1",
doi = "10.1007/s11926-016-0593-9",
language = "English (US)",
volume = "18",
journal = "Current Rheumatology Reports",
issn = "1523-3774",
publisher = "Current Science, Inc.",
number = "7",

}

TY - JOUR

T1 - Biologics in Pediatric Rheumatology

T2 - Quo Vadis?

AU - Sterba, Yonit

AU - Ilowite, Norman Todd

PY - 2016/7/1

Y1 - 2016/7/1

N2 - The past two decades have brought immense satisfaction to pediatric rheumatologists and families of children with rheumatologic diseases. We have been able to better classify, recognize, and diagnose rheumatologic diseases, but most importantly, the discovery of biologic therapies and their efficacy and relative safety in treating multiple rheumatologic conditions, improving quality of life for the patients we care for. We will review the advances of the past two decades and discuss potential areas for new discoveries.

AB - The past two decades have brought immense satisfaction to pediatric rheumatologists and families of children with rheumatologic diseases. We have been able to better classify, recognize, and diagnose rheumatologic diseases, but most importantly, the discovery of biologic therapies and their efficacy and relative safety in treating multiple rheumatologic conditions, improving quality of life for the patients we care for. We will review the advances of the past two decades and discuss potential areas for new discoveries.

KW - Abatacept

KW - IL-1 inhibitors

KW - IL-6 inhibitors

KW - Juvenile idiopathic arthritis (JIA)

KW - Rituximab

KW - TNF inhibitors

KW - Tofacitinib

UR - http://www.scopus.com/inward/record.url?scp=84976508941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976508941&partnerID=8YFLogxK

U2 - 10.1007/s11926-016-0593-9

DO - 10.1007/s11926-016-0593-9

M3 - Review article

VL - 18

JO - Current Rheumatology Reports

JF - Current Rheumatology Reports

SN - 1523-3774

IS - 7

M1 - 45

ER -